Show simple item record

OlympiAD final overall survival: olaparib versus chemotherapy treatment of physician's choice (TPC) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm)

dc.contributor.authorRobson, M
dc.contributor.authorIm, S
dc.contributor.authorSenkus, E
dc.contributor.authorXu, B
dc.contributor.authorDomchek, S
dc.contributor.authorMasuda, N
dc.contributor.authorDelaloge, S
dc.contributor.authorLi, W
dc.contributor.authorTung, N
dc.contributor.authorArmstrong, Anne C
dc.contributor.authorWu, W
dc.contributor.authorGoessl, C
dc.contributor.authorRunswick, S
dc.contributor.authorConte, P
dc.date.accessioned2019-09-11T09:09:18Z
dc.date.available2019-09-11T09:09:18Z
dc.date.issued2018en
dc.identifier.citationRobson ME, Im S-A, Senkus E, Xu B, Domchek S, Masuda N, et al. OlympiAD final overall survival: olaparib versus chemotherapy treatment of physician's choice (TPC) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). Cancer Res. 2018;78(13).en
dc.identifier.doi10.1158/1538-7445.AM2018-CT038en
dc.identifier.urihttp://hdl.handle.net/10541/622033
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1158/1538-7445.AM2018-CT038en
dc.titleOlympiAD final overall survival: olaparib versus chemotherapy treatment of physician's choice (TPC) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm)en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentMemorial Sloan Kettering Cancer Center, New York, NYen
dc.identifier.journalCancer Researchen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record